Cargando…

Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer

OBJECTIVE: To assess retrospectively the feasibility of intraoperative intraperitoneal (IP) chemotherapy with cisplatin in epithelial ovarian cancer. METHODS: IP chemotherapy during optimal staging surgery was performed in 10 patients who were diagnosed with primary epithelial ovarian cancers betwee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Myung Joo, Jung, Yong Wook, Seong, Seok Ju, Yoon, Bo Sung, Kim, Mi La, Joo, Won Deok, Song, Tae Jong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Gynecologic Oncology and Colposcopy 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325355/ https://www.ncbi.nlm.nih.gov/pubmed/22523624 http://dx.doi.org/10.3802/jgo.2012.23.2.91

Ejemplares similares

Survival outcomes and toxicity of intraoperative intraperitoneal chemotherapy in advanced epithelial ovarian cancer
por: Yoon, Ji-Young, et al.
Publicado: (2014)

Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy
por: Eoh, Kyung Jin, et al.
Publicado: (2017)

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
por: de Jong, Loek A. W., et al.
Publicado: (2023)

Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Intraoperative Chemotherapy in the Treatment of Advanced Epithelial Ovarian Cancer
por: Tentes, Antonios-Apostolos K., et al.
Publicado: (2012)

The addition of sodium thiosulphate to hyperthermic intraperitoneal chemotherapy with cisplatin in ovarian cancer
por: Glennon, Kate, et al.
Publicado: (2021)

Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer
por: Chen, Wei-Chun, et al.
Publicado: (2022)

Improvement of Intraperitoneal Chemotherapy for Rat Ovarian Cancer Using Cisplatin‐containing Microspheres
por: Kumagai, Seisuke, et al.
Publicado: (1996)

Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer
por: Ansaloni, L, et al.
Publicado: (2015)

Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study
por: He, Xiaoli, et al.
Publicado: (2021)

Systemic complications of the bidirectional intraoperative chemotherapy with intravenous ifosfamide and hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin plus doxorubicin
por: Hakeam, Hakeam, et al.
Publicado: (2019)

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
por: Riggs, McKayla J., et al.
Publicado: (2020)

Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report
por: Tempfer, Clemens B., et al.
Publicado: (2017)

A Modified Intraperitoneal Chemotherapy Regimen for Ovarian Cancer: Technique and Treatment Outcomes
por: Kim, Ji Hyun, et al.
Publicado: (2021)

NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer
por: Saldanha, Elroy, et al.
Publicado: (2022)

Hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer
por: Ko, Jieun, et al.
Publicado: (2021)

Bidirectional Intraoperative Chemotherapy Using Cisplatin and Ifosfamide for Intraperitoneal Mesothelioma in Severe Renal Impairment: A Case Report
por: Almesned, Razan K., et al.
Publicado: (2023)

Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer
por: Kim, S.I., et al.
Publicado: (2021)

Calculating the dose of cisplatin that is actually utilized in hyperthermic intraperitoneal chemotherapy among ovarian cancer patients
por: Wang, Wu-yun, et al.
Publicado: (2021)

The relationship between cisplatin resistance and histone deacetylase isoform overexpression in epithelial ovarian cancer cell lines
por: Kim, Min-Gyun, et al.
Publicado: (2012)

Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice.
por: Kondo, A., et al.
Publicado: (1996)

Evaluation of non-completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer
por: Chambers, Laura Moulton, et al.
Publicado: (2019)

Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study
por: Coccolini, Federico, et al.
Publicado: (2015)

The effect of dexmedetomidine on the adjuvant propofol requirement and intraoperative hemodynamics during remifentanil-based anesthesia
por: Kang, Woon-Seok, et al.
Publicado: (2012)

Hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer
por: Wu, Tao, et al.
Publicado: (2018)

Cost-effectiveness of hyperthermic intraperitoneal chemotherapy at primary cytoreduction of epithelial ovarian cancer based on residual disease status
por: Penn, Courtney A., et al.
Publicado: (2022)

Intraoperative metabolic changes associated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
por: Rubio-López, Jesús David, et al.
Publicado: (2023)

Hyperthermic intraoperative thoracoabdominal chemotherapy for stage IVB epithelial ovarian carcinoma
por: Brind'Amour, Alexandre, et al.
Publicado: (2020)

Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer
por: Lei, Ziying, et al.
Publicado: (2020)

Pharmacokinetics and toxicity of carboplatin used for hyperthermic intraperitoneal chemotherapy (HIPEC) in treatment of epithelial ovarian cancer
por: Mikkelsen, Mette Schou, et al.
Publicado: (2020)

Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study
por: Royer, B, et al.
Publicado: (2012)

A Dose-Finding Trial for Hyperthermic Intraperitoneal Cisplatin in Gynecological Cancer Patients Receiving Hyperthermic Intraperitoneal Chemotherapy
por: Chan, Chui-ying, et al.
Publicado: (2021)

Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial
por: Shi, Tingyan, et al.
Publicado: (2018)

Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer
por: Shin, Wonkyo, et al.
Publicado: (2018)

Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin
por: Markman, Maurie
Publicado: (2009)

Three ongoing intraperitoneal chemotherapy trials in ovarian cancer
por: Fujiwara, Keiichi
Publicado: (2012)

Hyperthermic intraperitoneal chemotherapy for ovarian cancer: is there a role?
por: Helm, C. William
Publicado: (2015)

Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer
por: Jewell, Andrea, et al.
Publicado: (2018)

Hyperthermic intraperitoneal chemotherapy in ovarian cancer: Qui Bono?
por: Spiliotis, John
Publicado: (2020)

Mechanistic Insights on Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
por: Huffman, Olivia G., et al.
Publicado: (2023)

Hyperthermic intrathoracic chemotherapy with cisplatin for ovarian cancer with pleural metastasis
por: Jun, Su Youn, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vdu2qg1l0qsg3cfjm8ib46qpj6